ALLMedicine™ Gastrointestinal Tumors Center

Mar 16th, 2023 - This study aimed to explore the predictive values of serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 199, CA125 and CA724 in the diagnosis of gastrointestinal tumors. Among patients treated for gastrointestinal tumors at the First ...

Mar 4th, 2023 - Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the GI tract. Despite this, they rarely occur, accounting for only 1% to 3% of all gastrointestinal tumors. This report describes a 53-year-old female patient with s...

Mar 3rd, 2023 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Mar 1st, 2023 - Gastrointestinal stromal tumors (GISTs) are connective tissue tumors representing a minority of gastrointestinal tumors. A 49-year-old woman was found to have a rectal mass in addition to uterine fibroids during work-up for abnormal uterine bleedi...

Mar 1st, 2023 - Hematotoxicity is a common side-effect of cytotoxic gastrointestinal (GI) cancer therapies. An unsolved problem is to predict the individual risk therefore to decide on treatment adaptions. We applied an established biomathematical prediction mode...

Aug 14th, 2008 - Therapeutic endoscopy plays a major role in the management of gastrointestinal (GI) neoplasia. Its indications can be generalized into four broad categories; to remove or obliterate neoplastic lesion, to palliate malignant obstruction, or to treat...

Mar 3rd, 2023 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Feb 21st, 2023 - This is an open-label, Phase Ib/II, multi-stage study of EMB-01 in patients with advanced gastrointestinal tumors including gastric cancer, hepatocellular cancer, cholangiocarcinoma cancer and colorectal cancer, who have EGFR/cMET gene alterations...

Feb 15th, 2023 - RGX-202-001 (ompenaclid) is a Phase 1, first-in-human, dose escalation and expansion study of RGX-202-01 as a single agent and in combination with FOLFIRI +/- bevacizumab. RGX-202-01 is a small molecule inhibitor of the creatine transporter SLC6a8...

Feb 15th, 2023 - To investigate the effect of Tislelizumab combined with XELOX in Neoadjuvant Therapy for gastrointestinal tumors. To explore new biomarkers that can predict the efficacy of combined immunotherapy, and to establish a clinical efficacy prediction mo...

Feb 13th, 2023 - The prevalence of HER2 alterations in pan-cancer indicates a broader range of application of HER2-targeted therapies. Tumors including breast cancer, gastrointestinal tumors, head and neck squamous tumors, bladder cancer, lung cancer and uterine t...

Oct 28th, 2022 - Gastroesophageal adenocarcinomas are a diverse group of diseases that we are starting to reclassify more and more on the basis of biomarker profiles, such as microsatellite status, human epidermal growth factor receptor 2 (HER2) and programmed dea.

Aug 11th, 2022 - Transcript: Benjamin Levy, MD:Let’s move away from chemotherapy and talk about more exciting targeted therapy, where we are seeing huge disease-free survival [DFS] advantages. Jonathan, can you give us an overview of the ADAURA [study; NCT0251110...

Aug 2nd, 2022 - The menu of tissue-agnostic oncology drug approvals is growing, generating new treatment options for patients with rare cancers and strengthening the rationale for broad next-generation sequencing (NGS), experts say. In June 2022, the FDA approv...

Jun 28th, 2022 - To date, oncologists have not seen much success with immunotherapy for neuroendocrine tumors (NETs). Xianxin Hua, MD, PhD, and a team at the University of Pennsylvania may be on the verge of changing that disappointing history. Hua, a professor o...

Jun 23rd, 2022 - The FDA has granted an accelerated approval to dabrafenib (Tafinlar) plus trametinib (Mekinist) for the treatment of adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors harboring a BRAF V600E mutation w...